Understanding the Variability in Weight Loss Drug Responses

Recent observations have highlighted a significant disparity in how individuals respond to glucagon-like peptide 1 (GLP-1) receptor agonists, such as Wegovy and Ozempic, which are increasingly used for weight loss. While many users report substantial weight loss and health benefits, a notable percentage experience minimal or no weight reduction, leading to feelings of frustration and failure.

Scientific American

Research indicates that approximately 12% of Americans have utilized GLP-1 drugs for weight loss, with real-world data suggesting that up to 25% of users may be classified as "nonresponders," defined as those losing less than 5% of their body weight after three months. Clinical trials conducted by Novo Nordisk found that up to 23% of participants fell into this category, and increasing the dosage of semaglutide did not significantly alter these outcomes.

Scientific American

The variability in responses is thought to stem from complex biological mechanisms. Factors such as sex, body composition, and underlying health conditions, particularly type 2 diabetes, have been shown to affect weight loss outcomes. For instance, men generally lose less weight than women when using these medications.

Scientific American

Genetic factors also play a crucial role in determining how individuals respond to GLP-1 drugs. Researchers, including those at the Mayo Clinic, have identified distinct biological phenotypes among individuals with obesity. For example, the "hungry brain" phenotype requires more calories to feel full, while the "hungry gut" phenotype may feel full quickly but experiences hunger soon after. A genetic score combining physiological and genetic data has been developed to predict these differences in caloric needs.

Scientific American

Additionally, variations in the neurobeachin gene have been linked to weight loss responses. Research from the Cleveland Clinic indicates that individuals with higher scores for neurobeachin variations are significantly more likely to be nonresponders to liraglutide, another GLP-1 drug.

Scientific American

Despite the promising insights, some studies have yielded inconsistent results regarding genetic influences on GLP-1 drug responses. A large study published in Nature Medicine involving over 10,000 individuals found no significant associations between genetic variants and weight-loss outcomes. Critics argue that more extensive datasets and research are necessary to draw definitive conclusions.

Scientific American

Experts in the field, such as Ruth Loos from the University of Copenhagen, emphasize the need for better scientific understanding before developing predictive genetic scores for treatment responses. Loos cautions that while genetics may offer insights, they are not deterministic, and environmental and lifestyle factors remain critical in weight management.

Scientific American

“People think your genetics is your destiny,” — Ruth Loos, Geneticist

Scientific American

“If we can identify ahead of time whether somebody will respond or not, it could save people a lot of money,” — Ruth Loos, Geneticist

Scientific American

Ongoing research aims to refine the understanding of genetic and biological factors influencing responses to GLP-1 drugs. As scientists continue to explore these variables, the hope is to develop more personalized treatment approaches that can enhance the effectiveness of weight-loss medications for diverse populations.

Scientific American